Shanghai Henlius Biotech, Inc. stated that it has signed an exclusive licence deal with Fosun Pharma to commercialise the anti-PD-1 monoclonal antibody (mAb) HANSIZHUANG, which Henlius independently created, in the US. The conditions of the deal state that Henlius will continue to be in charge of development, manufacture, and supply, while Fosun Pharma will have the authority to commercialise HANSIZHUANG in the US following approval.
A highly pure cystine peptide is now available from Evonik to help with formulation issues with cell culture media and other methods that are utilized in the creation and manufacturing of biopharmaceuticals. Globally accessible, cQrex AC is a chemically defined, highly soluble source of L-cystine that allows cells to get enough of this essential amino acid.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5561
Published Date: Jan 23, 2024
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The major factors driving the growth of the market are growth in making of personalized medications, advancement in technology for mammalian cell fermentation, and rising chronic disease.
The market size of mammalian cell fermentation technology is anticipated to attain a CAGR of 9% over the forecast period, i.e., 2024-2036.
The major players in the market are Shanghai Henlius Biotech, Inc., Evonik, Thermo Fisher Scientific Inc., General Electric, and others.
The Chinese hamster ovary (CHO) cell fermentation segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.